NEXT NUM ROWS=1
Friday, October 7th, 2022

 

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Effects of Rifaximin and Live Combined Bacillus subtilis and Enterococcus faecium in Diarrhea-Predominant Irritable Bowel Syndrome with Overgrowth of Small Intestinal Bacteria
Authors:  Zhe Luo, M.M., Xiao-Wei Li, M.D., Xiao-Hui Wang, M.M., Shao-Xin Wang, M.D., Hui Li, M.M., Chao Li, M.D., and Li-Hong Cui, M.D.
  Objective: Diarrhea and small intestinal bacterial overgrowth (SIBO) are key features in certain patients with irritable bowel syndrome (IBS). Rifaximin and Medilac-S are commonly used agents to treat IBS. This study aimed to observe the clinical effects of rifaximin and Medilac-S in diarrhea-predominant IBS (IBS-D) with SIBO.
Study Design:
In total, 136 IBS-D patients with SIBO were divided into 3 groups to receive Medilac-S (probiotic group), rifaximin (rifaximin group) or Medilac-S combined with rifaximin (combined group), respectively. Changes in the symptoms, which included severity and frequency of abdominal pain, frequency of defecation, and fecal characteristics, were recorded and scored. Blood samples were collected to measure serum interleukin–6 (IL-6), tumor necrosis factor–alpha (TNF-α), intestinal mucosal barrier-associated factor D–lactic acid (D-LA), and bacterial endotoxin lipopolysaccharide (LPS) using the enzyme-linked immunosorbent assay technique.
Results:
There were statistically significant differences in the scores for abdominal pain severity, abdominal pain frequency, defecation frequency, total symptoms, IL-6, TNF-α, D-LA, and LPS before and after treatment between the 3 groups (p<0.05 or p<0.01). After treatment there were statistically significant differences in abdominal pain severity score, abdominal pain frequency score, TNF-α, and LPS between the combined and probiotic groups (p<0.05 or p<0.01); in abdominal pain severity score between the combined and rifaximin groups (p<0.05); and in TNF-α and LPS between the rifaximin and probiotic groups (p<0.05 or p<0.01). There were also statistically significant differences in SIBO-negative conversion rate and significantly effective rate among the 3 groups after treatment, and the combined group showed better outcomes than the probiotic group (p<0.05).
Conclusion:
Overall, this study indicated that the treatment of IBS-D with SIBO with rifaximin and Medilac-S was highly effective in clinical settings.
Keywords:  Bacillus subtilis, combined treatment, Enterococcus faecium, irritable bowel syndrome, live combined Bacillus subtilis and Enterococcus faecium, probiotic, rifaximin, SIBO, small intestinal bacterial overgrowth
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from